Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 15/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | DRD2 | P14416 | 4/20 | 0.52 |
| ▸ | DRD3 | P35462 | 4/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2768536 | 0.91 | DRD4 (0.71) | DRD4CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL1759405 | 0.91 | DRD4 (0.71) | DRD4CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL1502000 | 0.91 | DRD4 (0.71) | DRD4CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL10319583 | 0.91 | DRD4 (0.71) | DRD4CYP1A2CYP3A4CYP2D6CYP2C9 | |
| Hydrochloric Acid SCHEMBL10670770 | 0.90 | DRD4 (0.69) | DRD4CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL3443710 | 0.87 | DRD4 (0.61) | DRD4CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL13229950 | 0.85 | DRD4 (0.59) | DRD4CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL5619541 | 0.83 | POLB (0.56) | DRD4 | |
| SCHEMBL8325714 | 0.83 | DRD4 (0.60) | DRD4CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL25081007 | 0.82 | DRD4 (0.56) | DRD4CYP1A2CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7906510-B2 | Amide derivative and pharmaceutical composition containing the same | Dainippon Sumito Pharma Co., Ltd. (JP) | 2011-03-15 | — | — | US | disclosed |
| US-7906510-B2 | Amide derivative and pharmaceutical composition containing the same | Dainippon Sumito Pharma Co., Ltd. (JP) | 2011-03-15 | — | — | US | disclosed |
| US-20100249399-A1 | AMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | Sumitomo Pharma Co., Ltd. (JP) | 2010-09-30 | — | — | US | disclosed |
| US-20100249399-A1 | AMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | Sumitomo Pharma Co., Ltd. (JP) | 2010-09-30 | — | — | US | disclosed |
| WO-2009104729-A1 | AMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | 大日本住友製薬株式会社 (JP) | 2009-08-27 | — | — | WO | disclosed |
| US-5561139-A | IMMUNOSUPPRESSANTS; SIDE EFFECT REDUCTION | ABBOTT LABORATORIES (US) | 1996-10-01 | — | — | US | disclosed |
| US-5530120-A | ANALOGS OF ASCOMYCIN AND FK-506 AS IMMUNOSUPPRESSANTS AND-MODULATORS; SIDE EFFECT REDUCTION | ABBOTT LABORATORIES (US) | 1996-06-25 | — | — | US | disclosed |
| WO-1994021634-A1 | SUBSTITUTED ALICYCLIC-ALIPHATIC AMINE-CONTAINING MACROCYCLIC IMMUNOMODULATORS | ABBOTT LABORATORIES (US) | 1994-09-29 | — | — | WO | disclosed |
| EP-0243959-B1 | SUBSTITUTED BENZAMIDE DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | Dainippon Pharmaceutical Co., Ltd. (JP) | 1992-08-19 | — | — | EP | disclosed |
| US-4870074-A | Substituted benzamide derivatives, for enhancing gastrointestinal motility | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 1989-09-26 | — | — | US | disclosed |
| EP-0243959-A1 | Substituted benzamide derivatives, processes for the preparation thereof, and pharmaceutical compositions containing the same | Dainippon Pharmaceutical Co., Ltd. (JP) | 1987-11-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249399-A1 | AMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | HTR4, MC2R, HTR1D | DRD4 277/4885CYP1A2 1665/4885CYP3A4 1068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.